Hugel Inc (145020 KS): Record High Performance in 2024; Continued Global Expansion to Drive Growth
Hugel achieves record sales and profits in 2024, driven by strong performance across all segments. US launch of toxin is expected in 1H25. Hugel...
410 Views
Hugel Inc (145020 KS): Record High Quarterly Sales and Operating Profit in 3Q; US Launch to Start
Hugel achieved revenue and operating profit of KRW105B and KRW53B in 3Q24, up 24% and 55%, YoY, respectively. The company plans to officially...
425 Views
Hugel Inc (145020 KS): Achieves Record High Revenue and Operating Profit in 4Q23
Hugel has received FDA approval for its botulinum toxin Letybo and becomes the only Korean company and one of the top 3 players globally that have...
601 Views
Hugel Inc (145020 KS): Favorable Court Ruling Paves US Entry; Record High 1Q Sales
Hugel wins favorable preliminary ruling in US, revealing strain theft claim baseless. The company plans to launch Letybo in 2H24 in US, while...
341 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
658 Views